Artiva Biotherapeutics (ARTV) Projected to Post Quarterly Earnings on Monday

Artiva Biotherapeutics (NASDAQ:ARTV) is expected to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.87) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 7:00 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.03. On average, analysts expect Artiva Biotherapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $5.01 on Friday. The company has a market cap of $123.85 million, a price-to-earnings ratio of -1.46 and a beta of 2.16. The business’s 50-day moving average is $4.97 and its two-hundred day moving average is $4.14. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.75.

Analyst Ratings Changes

Several brokerages have recently weighed in on ARTV. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the period. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $41,000. OMERS ADMINISTRATION Corp bought a new stake in Artiva Biotherapeutics during the fourth quarter valued at about $91,000. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at about $53,000. Finally, Renaissance Technologies LLC lifted its position in shares of Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after acquiring an additional 37,053 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.